Rheumatoid Arthritis Treatment Market expected to grow at a CAGR of 5.7% to reach US$ 79.1 Bn by the end of 2033

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation and pain in the joints, leading to reduced mobility and disability. The global rheumatoid arthritis treatment market has been expanding rapidly due to the increasing prevalence of the disease, rising awareness about early diagnosis, and the availability of effective treatment options.

The global revenue from the rheumatoid arthritis treatment market stands at US$ 42.9 Bn in 2022, with the global market expected to grow at a CAGR of 5.7% to reach a valuation of approximately US$ 79.1 Bn by the end of 2033.

Need More Insights on Competitor Analysis of the Rheumatoid Arthritis Treatment Market, Request for Sample@ https://www.persistencemarketresearch.com/samples/22555

The market is primarily driven by the adoption of biologics and disease-modifying antirheumatic drugs (DMARDs) for the treatment of RA. Biologics, such as tumor necrosis factor inhibitors, interleukin inhibitors, and B-cell inhibitors, have revolutionized the treatment of RA by providing targeted therapy that reduces inflammation and prevents joint damage. DMARDs, such as methotrexate and sulfasalazine, are also widely used in the treatment of RA.

Companies

Sanofi S.A.
Pfizer Inc.
Johnson & Johnson
AbbVie Inc.
Eli Lilly & Company
Amgen Inc.
Bristol-Myers Squibb Company
F. Hoffman-La Roche AG
Cipla, Inc.
Sun Pharmaceutical Industries Ltd.
Sobi Inc.
Novartis AG ( Sandoz)
UCB S.A.

If You Want To Know The Business Opportunity/Market Value, Purchase The Premium Insight @ https://www.persistencemarketresearch.com/checkout/22555

North America is the largest market for rheumatoid arthritis treatment, followed by Europe and the Asia Pacific. The high prevalence of RA in North America, coupled with the availability of advanced healthcare infrastructure and favorable reimbursement policies, has contributed to the dominance of this region in the market. The Asia Pacific region is expected to witness significant growth in the coming years due to the rising incidence of RA and increasing healthcare spending.

Some of the key players in the rheumatoid arthritis treatment market include AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi, and UCB S.A. These companies are investing heavily in research and development activities to develop new and innovative treatments for RA.

Despite the growth potential, the rheumatoid arthritis treatment market faces several challenges, including the high cost of biologics and the risk of adverse events associated with these drugs. The availability of generic drugs is also expected to hinder market growth. However, the development of biosimilars, which are biologic drugs that are highly similar to existing biologics, is expected to create new opportunities for players in the market.

Competition Landscape

The main participants in the global market for rheumatoid arthritis treatment generally employ co-commercialization and distribution partnerships as marketing and distribution strategies.

Throughout the anticipated period, the introduction of novel JAK inhibitors for rheumatoid arthritis will stimulate market growth.

Some key instances of development within the market include:

Etanercept, a drug manufactured locally by Cipla that is prescribed to treat rheumatic disorders, was released in March 2018. The drug known by the brand name Etacept will be manufactured by Shanghai CP Guojian Pharmaceutical Co. in China and marketed by Cipla in India according to the cooperation agreement.
Avsola, a biosimilar version of the popular rheumatoid arthritis medicine Remicade manufactured by Johnson & Johnson, received approval from the U.S. Food and Drug Administration in December 2019.

If you want to Purchase Specific Insights by Segment/Region/Competitor, Request For Customization @ https://www.persistencemarketresearch.com/request-customization/22555

Key Segments Covered in Global Rheumatoid Arthritis Treatment Market Research

Therapy:

Symptomatic Treatment
Intermediate Corticosteroid Therapies
Stem Cell Therapy
Disease Modifying Anti-rheumatic Drug (DMARD)
Conventional DMARDs
Biologic DMARDs

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Drug Stores

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Top Market Research Report:

Non-Melanoma Skin Cancer Market: https://www.persistencemarketresearch.com/market-research/non-melanoma-skin-cancer-market.asp

Plastic Wound Retractor Market: https://www.persistencemarketresearch.com/market-research/plastic-wound-retractor-market.asp

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.